Software company DocuSign’s (DOCU) stock scored a rating upgrade from Hold to Buy from William Blair, thanks to the optimism ...
The biotech is exploring opportunities for a reverse merger or other business combinations. CFO and now interim CEO Anup ...
Confluent (NASDAQ:CFLT – Get Free Report)‘s stock had its “outperform” rating reissued by analysts at William Blair in a ...
1d
Fintel on MSNWilliam Blair Initiates Coverage of Butterfly Network (BFLY) with Outperform RecommendationFintel reports that on March 17, 2025, William Blair initiated coverage of Butterfly Network (NYSE:BFLY) with a Outperform ...
1d
Fintel on MSNWilliam Blair Upgrades DocuSign (DOCU)Fintel reports that on March 17, 2025, William Blair upgraded their outlook for DocuSign (NasdaqGS:DOCU) from Market Perform ...
Analysts at William Blair lowered their Q1 2025 earnings estimates for Legend Biotech in a research report issued to clients ...
JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...
The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.
William Blair analyst Matthew Phipps last night upgraded Genmab (GMAB) to Outperform from Market Perform without a price target. after the ...
The embedded finance company, which posted a loss last year, hired Citi to explore its strategic options and named an interim ...
Investing.com -- William Blair analysts issued a cautionary note on Palantir Technologies (NASDAQ:PLTR), highlighting potential downside risk for the stock despite continued commercial momentum.
The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results